BioCentury | Mar 23, 2015
Finance

Alize's assets

...the clinic in 2017. Alize Pharma III has exclusive worldwide rights to the program from New Paradigm Therapeutics Inc....
BioCentury | Dec 15, 2014
Company News

New Paradigm Therapeutics, Alize Pharma deal

...Alize received exclusive, worldwide rights from New Paradigm Therapeutics to develop and commercialize peptides derived from a fragment...
...a single IGFBP2 peptide up to clinical development and then out-license or divest the program. New Paradigm Therapeutics...
...divestment revenues. Alize set up a newco, Alize Pharma III S.A.S., to develop the peptides. New Paradigm Therapeutics Inc....
Items per page:
1 - 2 of 2
BioCentury | Mar 23, 2015
Finance

Alize's assets

...the clinic in 2017. Alize Pharma III has exclusive worldwide rights to the program from New Paradigm Therapeutics Inc....
BioCentury | Dec 15, 2014
Company News

New Paradigm Therapeutics, Alize Pharma deal

...Alize received exclusive, worldwide rights from New Paradigm Therapeutics to develop and commercialize peptides derived from a fragment...
...a single IGFBP2 peptide up to clinical development and then out-license or divest the program. New Paradigm Therapeutics...
...divestment revenues. Alize set up a newco, Alize Pharma III S.A.S., to develop the peptides. New Paradigm Therapeutics Inc....
Items per page:
1 - 2 of 2